Third generation EGFR TKIs: Current data and future directions

• Main Authors: Tan, C.-S, Kumarakulasinghe, N.B, Huang, Y.-Q, Ang, Y.L.E, Choo, J.R.-E, Goh, B.-C, Soo, R.A
• Other Authors: DEPT OF PHARMACOLOGY
• Format: Review
• Published: 2020
• Subjects: avitinib; brigatinib; circulating tumor DNA; epidermal growth factor receptor; epidermal growth factor receptor kinase inhibitor; erlotinib; fibroblast growth factor receptor 1; gefitinib; K ras protein; mavelertinib; mitogen activated protein kinase; naquotinib; nazartinib; olmutinib; osimertinib; pemetrexed; phosphatidylinositol 3 kinase; platinum derivative; rociletinib; unclassified drug; yh 25448; piperazine derivative; protein kinase inhibitor; acne; anemia; C797S gene; cancer growth; cell transformation; central nervous system metastasis; circulating tumor cell; decreased appetite; diarrhea; disease control; drug development; drug dose escalation; drug dose increase; drug efficacy; drug indication; drug resistance; drug response; drug safety; drug selectivity; drug tolerance; drug withdrawal; dry skin; exon; fatigue; FGFR1 gene; gene; gene amplification; gene mutation; hepatitis B; human; hypertransaminasemia; incidence; interstitial lung disease; maculopapular rash; MAPK gene; nausea; non small cell lung cancer; oncogene K ras; paronychia; patient-reported outcome; PIK3CA gene; pneumonia; progression free survival; pruritus; QT prolongation; rash; Review; rhinorrhea; stomatitis; T790 M gene; tumor biopsy; animal; antagonists and inhibitors; genetics; metabolism; mutation; Animals; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Mutation; Piperazines; Protein Kinase Inhibitors
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/181215
• Institution: National University of Singapore

10.1186/s12943-018-0778-0